BridgePoint Medical, manufacturers of chronic total occlusion and
peripheral vascular devices, has signed definitive agreements to exclusively
license the rights to its peripheral vascular devices to Covidien.
Among BridgePoint Medical’s products included in the deal were the
BigBoss catheter, Mantaray catheters and the Mantaray guidewire. Present assets
that will remain with BridgePoint Medical include its employees, chronic total
occlusion products and all other non-vascular applications.
The specific terms of the agreement were not disclosed at the time of
the announcement.
In other Covidien news, José E. Almeida has been named chairman
by the company’s board of directors effective March 13. In July, Almeida
became president, CEO and a member of Covidien’s board when Richard J.
Meelia, the company’s former CEO, president and chairman, retired. In
addition, Stacy Enxing Seng, a co-founder and former executive of ev3 Inc., an
endovascular company acquired by Covidien in 2010, has been named president of
Covidien’s Vascular Therapies Global Business Unit.